Fieldpoint Private Securities LLC Has $400,000 Holdings in Novartis AG (NVS)
Fieldpoint Private Securities LLC boosted its holdings in Novartis AG (NYSE:NVS) by 25.9% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,657 shares of the company’s stock after purchasing an additional 957 shares during the quarter. Fieldpoint Private Securities LLC’s holdings in Novartis were worth $400,000 at the end of the most recent reporting period.
Other institutional investors have also modified their holdings of the company. WFG Advisors LP raised its stake in Novartis by 38.1% in the 2nd quarter. WFG Advisors LP now owns 1,221 shares of the company’s stock worth $102,000 after purchasing an additional 337 shares in the last quarter. Wealthcare Advisory Partners LLC acquired a new position in shares of Novartis in the 3rd quarter valued at approximately $106,000. Cable Hill Partners LLC raised its position in shares of Novartis by 588.8% in the 3rd quarter. Cable Hill Partners LLC now owns 1,295 shares of the company’s stock valued at $112,000 after buying an additional 1,107 shares in the last quarter. Harding Loevner LP acquired a new position in shares of Novartis in the 2nd quarter valued at approximately $146,000. Finally, Mosaic Family Wealth LLC raised its position in shares of Novartis by 6.1% in the 2nd quarter. Mosaic Family Wealth LLC now owns 2,144 shares of the company’s stock valued at $179,000 after buying an additional 123 shares in the last quarter. Institutional investors and hedge funds own 10.87% of the company’s stock.
NVS has been the subject of several analyst reports. Zacks Investment Research upgraded shares of Novartis from a “hold” rating to a “buy” rating and set a $96.00 target price for the company in a research report on Tuesday, September 19th. BidaskClub upgraded shares of Novartis from a “sell” rating to a “hold” rating in a research report on Saturday, August 19th. Leerink Swann boosted their target price on shares of Novartis from $89.00 to $91.00 and gave the company a “market perform” rating in a research report on Monday, October 23rd. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of Novartis in a research report on Tuesday, October 10th. Four analysts have rated the stock with a sell rating, ten have given a hold rating and four have given a buy rating to the company’s stock. Novartis has a consensus rating of “Hold” and an average target price of $85.32.
Shares of Novartis AG (NYSE:NVS) traded up $0.20 during trading on Thursday, hitting $84.66. 879,300 shares of the company traded hands, compared to its average volume of 2,248,176. The company has a market cap of $199,798.16, a price-to-earnings ratio of 17.78, a PEG ratio of 2.68 and a beta of 0.73. The company has a quick ratio of 0.81, a current ratio of 1.08 and a debt-to-equity ratio of 0.32. Novartis AG has a 12 month low of $69.53 and a 12 month high of $86.90.
Novartis (NYSE:NVS) last announced its quarterly earnings results on Tuesday, October 24th. The company reported $1.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.25 by $0.04. The company had revenue of $12.41 billion for the quarter, compared to analyst estimates of $12.21 billion. Novartis had a net margin of 13.73% and a return on equity of 15.77%. The firm’s revenue was up 2.4% on a year-over-year basis. During the same period in the previous year, the firm posted $1.23 EPS. equities research analysts predict that Novartis AG will post 4.75 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This article was first published by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/fieldpoint-private-securities-llc-has-400000-holdings-in-novartis-ag-nvs/1763838.html.
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with Analyst Ratings Network's FREE daily email newsletter.